BR112016029157A8 - processo para purificar a proteína de fusão tnfr:fc - Google Patents
processo para purificar a proteína de fusão tnfr:fcInfo
- Publication number
- BR112016029157A8 BR112016029157A8 BR112016029157A BR112016029157A BR112016029157A8 BR 112016029157 A8 BR112016029157 A8 BR 112016029157A8 BR 112016029157 A BR112016029157 A BR 112016029157A BR 112016029157 A BR112016029157 A BR 112016029157A BR 112016029157 A8 BR112016029157 A8 BR 112016029157A8
- Authority
- BR
- Brazil
- Prior art keywords
- tnfr
- fusion protein
- purifying
- present
- hcp
- Prior art date
Links
- 108091006020 Fc-tagged proteins Proteins 0.000 title abstract 5
- 238000000034 method Methods 0.000 title abstract 3
- 102000004190 Enzymes Human genes 0.000 abstract 1
- 108090000790 Enzymes Proteins 0.000 abstract 1
- 238000001042 affinity chromatography Methods 0.000 abstract 1
- 230000000593 degrading effect Effects 0.000 abstract 1
- 238000012434 mixed-mode chromatography Methods 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 238000000746 purification Methods 0.000 abstract 1
Classifications
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
- B01D15/08—Selective adsorption, e.g. chromatography
- B01D15/10—Selective adsorption, e.g. chromatography characterised by constructional or operational features
- B01D15/12—Selective adsorption, e.g. chromatography characterised by constructional or operational features relating to the preparation of the feed
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
- B01D15/08—Selective adsorption, e.g. chromatography
- B01D15/10—Selective adsorption, e.g. chromatography characterised by constructional or operational features
- B01D15/20—Selective adsorption, e.g. chromatography characterised by constructional or operational features relating to the conditioning of the sorbent material
- B01D15/203—Equilibration or regeneration
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
- B01D15/08—Selective adsorption, e.g. chromatography
- B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
- B01D15/30—Partition chromatography
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
- B01D15/08—Selective adsorption, e.g. chromatography
- B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
- B01D15/36—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving ionic interaction, e.g. ion-exchange, ion-pair, ion-suppression or ion-exclusion
- B01D15/361—Ion-exchange
- B01D15/363—Anion-exchange
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
- B01D15/08—Selective adsorption, e.g. chromatography
- B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
- B01D15/38—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving specific interaction not covered by one or more of groups B01D15/265 and B01D15/30 - B01D15/36, e.g. affinity, ligand exchange or chiral chromatography
- B01D15/3804—Affinity chromatography
- B01D15/3809—Affinity chromatography of the antigen-antibody type, e.g. protein A, G or L chromatography
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
- B01D15/08—Selective adsorption, e.g. chromatography
- B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
- B01D15/38—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving specific interaction not covered by one or more of groups B01D15/265 and B01D15/30 - B01D15/36, e.g. affinity, ligand exchange or chiral chromatography
- B01D15/3847—Multimodal interactions
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
- B01D15/08—Selective adsorption, e.g. chromatography
- B01D15/42—Selective adsorption, e.g. chromatography characterised by the development mode, e.g. by displacement or by elution
- B01D15/424—Elution mode
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
- C07K14/7151—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for tumor necrosis factor [TNF], for lymphotoxin [LT]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Analytical Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Cell Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Toxicology (AREA)
- Peptides Or Proteins (AREA)
- Enzymes And Modification Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN1919MU2014 | 2014-06-13 | ||
| PCT/IB2015/054494 WO2015189832A1 (en) | 2014-06-13 | 2015-06-13 | Process for the purification of tnfr:fc fusion protein |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| BR112016029157A2 BR112016029157A2 (pt) | 2017-08-22 |
| BR112016029157A8 true BR112016029157A8 (pt) | 2021-07-06 |
Family
ID=53524922
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112016029157A BR112016029157A8 (pt) | 2014-06-13 | 2015-06-13 | processo para purificar a proteína de fusão tnfr:fc |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US10556942B2 (enExample) |
| EP (1) | EP3155009A1 (enExample) |
| JP (1) | JP6747985B2 (enExample) |
| CN (1) | CN106536565A (enExample) |
| AU (1) | AU2015273049B2 (enExample) |
| BR (1) | BR112016029157A8 (enExample) |
| CA (1) | CA2951766A1 (enExample) |
| MA (1) | MA40232A (enExample) |
| MX (1) | MX2016016318A (enExample) |
| PH (1) | PH12016502482A1 (enExample) |
| RU (1) | RU2698654C2 (enExample) |
| WO (1) | WO2015189832A1 (enExample) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11566082B2 (en) | 2014-11-17 | 2023-01-31 | Cytiva Bioprocess R&D Ab | Mutated immunoglobulin-binding polypeptides |
| KR20170138426A (ko) * | 2015-03-13 | 2017-12-15 | 삼성바이오에피스 주식회사 | 항-tnf-알파 폴리펩티드 조성물 및 그 용도 |
| CN109311949B (zh) | 2016-05-11 | 2022-09-16 | 思拓凡生物工艺研发有限公司 | 储存分离基质的方法 |
| JP7031934B2 (ja) | 2016-05-11 | 2022-03-08 | サイティバ・バイオプロセス・アールアンドディ・アクチボラグ | 分離マトリックス |
| US10730908B2 (en) | 2016-05-11 | 2020-08-04 | Ge Healthcare Bioprocess R&D Ab | Separation method |
| US10703774B2 (en) | 2016-09-30 | 2020-07-07 | Ge Healthcare Bioprocess R&D Ab | Separation method |
| EP3455243B1 (en) | 2016-05-11 | 2021-03-24 | Cytiva BioProcess R&D AB | Separation matrix |
| US10654887B2 (en) | 2016-05-11 | 2020-05-19 | Ge Healthcare Bio-Process R&D Ab | Separation matrix |
| US10889615B2 (en) | 2016-05-11 | 2021-01-12 | Cytiva Bioprocess R&D Ab | Mutated immunoglobulin-binding polypeptides |
| ES2909833T3 (es) | 2016-05-11 | 2022-05-10 | Cytiva Bioprocess R & D Ab | Método de limpieza y/o desinfección de una matriz de separación |
| US12448411B2 (en) | 2016-09-30 | 2025-10-21 | Cytiva Bioprocess R&D Ab | Separation method |
| EP3668985B1 (en) * | 2017-08-17 | 2021-06-16 | Just-Evotec Biologics, Inc. | Method of purifying glycosylated protein from host cell galectins and other contaminants |
| US20210130396A1 (en) * | 2017-08-30 | 2021-05-06 | Ares Trading S.A. | Method for purifying proteins |
| US11952399B2 (en) * | 2018-12-18 | 2024-04-09 | Amgen Inc. | Methods for purifying proteins |
| AU2020216368B2 (en) * | 2019-01-30 | 2025-04-24 | Amgen Inc. | Aflibercept attributes and methods of characterizing and modifying thereof |
| KR102286892B1 (ko) * | 2019-07-08 | 2021-08-06 | 삼천당제약주식회사 | 안과용 단백질 제제의 정제방법 |
| CN112876567A (zh) * | 2019-11-29 | 2021-06-01 | 广东菲鹏制药股份有限公司 | Fc融合蛋白及其纯化方法 |
| WO2021181417A1 (en) * | 2020-03-11 | 2021-09-16 | Dr. Reddy's Laboratories Limited | METHOD OF PURIFYING AN Fc-FUSION PROTEIN |
| CN113563469A (zh) * | 2020-04-28 | 2021-10-29 | 江苏中新医药有限公司 | 高回收率纯化阿达木单抗的方法 |
| WO2022234412A1 (en) * | 2021-05-03 | 2022-11-10 | Lupin Limited | A process for purification of fc-fusion proteins |
| AU2022358612A1 (en) * | 2021-09-28 | 2024-04-11 | Kashiv Biosciences, Llc | An improved process of purification of fusion protein |
| WO2023053030A1 (en) * | 2021-09-28 | 2023-04-06 | Kashiv Biosciences, Llc | An improved process for purification of protein |
| WO2023053032A1 (en) * | 2021-09-28 | 2023-04-06 | Kashiv Biosciences, Llc | An improved process for purification of fusion protein |
| AU2022369694B2 (en) * | 2021-10-19 | 2025-10-09 | Alteogen, Inc | Method for purifying fusion protein having igg fc domain |
| WO2023095665A1 (ja) * | 2021-11-29 | 2023-06-01 | 東ソー株式会社 | 抗体の分離方法 |
| CN119060168A (zh) * | 2024-09-26 | 2024-12-03 | 广东丸美生物技术股份有限公司 | 一种具有低电导率的重组胶原蛋白溶液及其制备方法和应用 |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2021284C1 (ru) * | 1991-05-30 | 1994-10-15 | Всесоюзный научно-исследовательский институт технологии кровезаменителей и гормональных препаратов | Способ очистки клинических фракций декстрана |
| US7294481B1 (en) | 1999-01-05 | 2007-11-13 | Immunex Corporation | Method for producing recombinant proteins |
| DK1478394T3 (da) | 2002-02-27 | 2008-10-13 | Immunex Corp | Stabiliseret TNFR-Fc formulation med arginin |
| CA2516518A1 (en) | 2003-02-28 | 2004-09-10 | Lonza Biologics Plc. | Antibody purification by protein a and ion exchange chromatography |
| WO2007109163A2 (en) * | 2006-03-16 | 2007-09-27 | Amgen Inc | Wash buffer and method of using |
| CA2661748C (en) * | 2006-08-28 | 2016-02-09 | Alex Eon-Duval | Process for the purification of fc-containing proteins |
| JP2010501622A (ja) * | 2006-08-28 | 2010-01-21 | アレス トレーディング ソシエテ アノニム | Ｆｃ−融合タンパク質の精製法 |
| AU2008314689A1 (en) * | 2007-10-22 | 2009-04-30 | Merck Serono S.A. | Method for purifying an Fc-containing protein |
| CA2717129A1 (en) * | 2008-02-29 | 2009-09-11 | Biogen Idec Ma Inc. | Purified immunoglobulin fusion proteins and methods of their purification |
| CN102272154A (zh) * | 2008-10-29 | 2011-12-07 | 惠氏有限责任公司 | 单域抗原结合性分子的纯化方法 |
| US9284347B2 (en) * | 2010-01-22 | 2016-03-15 | Boehringer Ingelheim International Gmbh | Chromatographic method for purifying FC-containing proteins |
| WO2012176158A1 (en) * | 2011-06-24 | 2012-12-27 | Dr. Reddy's Laboratories Limited | Purification of chimeric protein |
| AU2012282960A1 (en) | 2011-07-08 | 2014-01-16 | Merck Sharp & Dohme Corp. | Method for purifying Fc-fusion protein |
| ES2651483T3 (es) * | 2011-08-17 | 2018-01-26 | Ares Trading S.A. | Método para preparar la forma activa de la proteína de fusión TNRF-Fc |
| US9249182B2 (en) | 2012-05-24 | 2016-02-02 | Abbvie, Inc. | Purification of antibodies using hydrophobic interaction chromatography |
| PL2895188T3 (pl) * | 2012-09-11 | 2018-06-29 | Coherus Biosciences, Inc. | Prawidłowo pofałdowany etanercept o wysokiej czystości i doskonałej wydajności |
| CN102911250B (zh) * | 2012-09-29 | 2014-04-16 | 浙江海正药业股份有限公司 | 酸性重组蛋白药物的纯化方法 |
| US9649383B2 (en) * | 2012-11-19 | 2017-05-16 | Merck Sharp & Dohme Corp. | Liquid formulations for TNFR:Fc fusion proteins |
| HUE064450T2 (hu) * | 2013-03-14 | 2024-03-28 | Amgen Inc | Kiszivárgott affinitás tisztító ligandum eltávolítása |
| US8946395B1 (en) * | 2013-10-18 | 2015-02-03 | Abbvie Inc. | Purification of proteins using hydrophobic interaction chromatography |
-
2015
- 2015-06-13 AU AU2015273049A patent/AU2015273049B2/en not_active Ceased
- 2015-06-13 JP JP2016572703A patent/JP6747985B2/ja not_active Expired - Fee Related
- 2015-06-13 MA MA040232A patent/MA40232A/fr unknown
- 2015-06-13 BR BR112016029157A patent/BR112016029157A8/pt not_active Application Discontinuation
- 2015-06-13 CN CN201580038801.XA patent/CN106536565A/zh active Pending
- 2015-06-13 MX MX2016016318A patent/MX2016016318A/es unknown
- 2015-06-13 CA CA2951766A patent/CA2951766A1/en not_active Abandoned
- 2015-06-13 EP EP15734731.1A patent/EP3155009A1/en not_active Withdrawn
- 2015-06-13 WO PCT/IB2015/054494 patent/WO2015189832A1/en not_active Ceased
- 2015-06-13 RU RU2017100005A patent/RU2698654C2/ru active
- 2015-06-13 US US15/318,489 patent/US10556942B2/en active Active
-
2016
- 2016-12-13 PH PH12016502482A patent/PH12016502482A1/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2015273049A1 (en) | 2017-01-12 |
| EP3155009A1 (en) | 2017-04-19 |
| MA40232A (fr) | 2017-04-19 |
| RU2017100005A (ru) | 2018-07-13 |
| RU2698654C2 (ru) | 2019-08-28 |
| AU2015273049B2 (en) | 2019-11-14 |
| US20170152298A1 (en) | 2017-06-01 |
| PH12016502482A1 (en) | 2017-04-10 |
| JP6747985B2 (ja) | 2020-08-26 |
| CN106536565A (zh) | 2017-03-22 |
| JP2017521389A (ja) | 2017-08-03 |
| WO2015189832A1 (en) | 2015-12-17 |
| MX2016016318A (es) | 2017-06-12 |
| US10556942B2 (en) | 2020-02-11 |
| CA2951766A1 (en) | 2015-12-17 |
| BR112016029157A2 (pt) | 2017-08-22 |
| RU2017100005A3 (enExample) | 2019-02-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112016029157A8 (pt) | processo para purificar a proteína de fusão tnfr:fc | |
| BR112018075516A2 (pt) | purificação de anticorpos multiespecíficos | |
| BR112018011567A2 (pt) | método de purificação de uma proteína de interesse, e, uso de um método. | |
| BR112018009312A8 (pt) | método para promover eficiência de purificação de polipeptídeo contendo região de fc | |
| CL2018000108A1 (es) | Moléculas de anticuerpo que se unen a cd22 | |
| BR112016003196A8 (pt) | método para separar anticorpos biespecíficos | |
| PH12017500402A1 (en) | Anti-glucagon antibodies and uses thereof | |
| BR112018001161A2 (pt) | proteínas de fusão de ligação a gitr multiespecíficas e multivalentes | |
| BR112018010673A2 (pt) | moléculas de anticorpo para april e seus usos | |
| JO3532B1 (ar) | الأجسام المضادة لمضاد انترلوكين-33 واستعمالاتها | |
| BR112018003127A2 (pt) | purificação de fkpa e usos do mesmo para produzir polipeptídeos recombinantes | |
| BR112015004467A2 (pt) | método para controlar a heterogeneidade de proteínas | |
| CU20170039A7 (es) | Método de purificación del anticuerpo humanizado 9e4 | |
| BR112016025792A2 (pt) | meios e processos para tratamento de cmv | |
| BR102015012091A8 (pt) | método para a preparação de uma solução de albumina humana, e, composição | |
| BR112017008962A2 (pt) | proteínas de fusão inibidoras de c1 esterase e usos das mesmas | |
| BR112015021332A2 (pt) | sal de sódio de ácido (2s, 5r)-6-benzilóxi-7-oxo-1,6-diaza-biciclo [3.2.1] octano-2-carboxílico e sua preparação | |
| BR112014027991A2 (pt) | agentes para neutralização de influenza | |
| BR112016017107B8 (pt) | Coluna de destilação | |
| BR112018076666A2 (pt) | cilastatina para uso no tratamento de sépsis | |
| BR112017001966A2 (pt) | ?método para produzir variantes com um fc com sialilação melhorada? | |
| BR112016022508A2 (pt) | anticorpos contra hpa-1a | |
| BR112017019207A2 (pt) | recuperação e/ou reutilização de catalisador de paládio após acoplamento de suzuki | |
| BR112017009344A2 (pt) | método para a produção de um material compósito, e dispositivo para a produção de um material compósito | |
| EA201691834A1 (ru) | Новый способ очистки гонадотропина |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] |
Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NAO 10196/2001, QUE MODIFICOU A LEI NAO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUAANCIA PRA VIA DA ANVISA. CONSIDERANDO A APROVAA AO DOS TERMOS DO PARECER NAO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NAO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDAANCIAS CABA-VEIS. |
|
| B07G | Grant request does not fulfill article 229-c lpi (prior consent of anvisa) [chapter 7.7 patent gazette] |
Free format text: NOTIFICACAO DE DEVOLUCAO DO PEDIDO EM FUNCAO DA REVOGACAO DO ART. 229-C DA LEI NO 9.279, DE 1996, POR FORCA DA LEI NO 14.195, DE 2021 |
|
| B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
| B11B | Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements |